Dendreon's Provenge Questioned in NEJM
The authors of the IMPACT study published in this week's NEJM found no outside variable, including use of the chemotherapy drug Taxotere, explains away the survival difference favoring Provenge.
Provenge is priced at $93,000 per course of treatment, which Longo labels as a "concern."
"The high cost may affect use. It is also uncertain what role sipuleucel-T [Provenge] will ultimately play in the treatment of prostate cancer, given the other promising treatments in development," he writes. Longo goes on to mention other prostate cancer drugs in late-stage clinical trials, including Johnson & Johnson's (JNJ) abiraterone and Medivation's (MDVN) MDV3100.
"The prospects for improved therapy for prostate cancer have never been so encouraging, " Longo concludes at the end of his editorial. "The poor prognosis for men with prostate cancer will probably be substantially improved by the findings that emerge from ongoing clinical research."David Miller of Biotech Stock Research, an independent biotech investment newsletter and a long-time follower of Dendreon, dismissed Longo's arguments as "mostly tired, ignorant or wrong." Meantime, Dendreon will report financial results for the second quarter on Aug. 3. Analysts are expecting Provenge sales of approximately $4 million in the drug's first quarter since launch. -- Reported by Adam Feuerstein in Boston. Follow Adam Feuerstein on Twitter.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV